|
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease Clinical research trials and Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease. Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease clinical trial. Subjects frequently obtain the most expert healthcare possible for their Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease  Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
For Condition: Alzheimer Disease
Status: Completed
Sponsor(s): National Institute on Aging (NIA) , Burke Medical Research Institute
Synopsis: The purpose of this study is to evaluate the effectiveness of a nutritional supplement that has been developed to improve the brain function of a patient with Alzheimer's disease.
Details: The ability of the brain to use its major fuel, the sugar glucose, is reduced in Alzheimer's disease. A nutritional supplement has been developed to improve the function of the Alzheimer brain by increasing its ability to use sugar effectively. The ingredients of the supplement are natural products, and are found in the normal American diet. Results have been encouraging in open trials where the patients knew they were taking the active medicine. Patients are now being invited to participate in a placebo-controlled trial lasting 3 months, followed by a 3-month open label trial where all patients will receive the active preparation. This is a double-blind, placebo-controlled, parallel-group, 3 month trial followed by a 3-month open-label period, of a nutritional supplement designed to improve brain metabolism and function in patients with Alzheimer's disease (AD). The design of the nutritional supplement is based on replicated observations of abnormalities in mitochondria in AD. The constituents of the nutritional supplement are components of the normal American diet, and are classified by the FDA as GRAS (Generally Regarded As Safe). Results with the supplement have been favorable in preliminary, open trials (eg mean improvement in MMSE score of +4.9, range +3 to +8, n = 7, P <0.0004). During the placebo-controlled portion of the trial, half of the participants will receive the active preparation and half a sugar pill. During this first phase, neither the patients nor those testing them will know who is taking active medicine and who is taking placebo. The active supplement or placebo are taken as 1 tablespoon twice a day, between meals. If desired, the supplement or placebo can be stirred into, or washed down with, water, coffee or tea without milk or sugar, or the soft drink TAB. Patient visits to the Burke Medical Research Institute will be once a month, after the screening and baseline visits. The supplement is taken as one tablespoon of a fluid, between meals. Since other sugars or citrate can be expected to interfere with the actions of the supplements, food or drinks containing sugar or citrate and diet drinks containing citrate are to be avoided for 1 1/2 hour before and 1 1/2 hour after taking the supplement. No significant adverse events have been associated with this supplement. However, standard precautions for patient safety are being taken, including medical examination and clinical laboratory tests at screening and at the completion of the double-blind and open-label phases.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria include: - A documented diagnosis of Alzheimer's disease; - MMSE score between 10 and 26 inclusive; - A reliable caregiver to ensure compliance. Exclusion criteria include: - diabetes, unstable medical illness, myocardial infarction or cancer diagnosed within the previous 12 months, or treatment with systemic steroids. - Patients being treated for depression or other psychiatric symptomatology are eligible, if their symptoms are under control on a stable dose of medication
Total Enrollment: 40
Location and Contact Information:
Overall Study Official:
JohnBlass, Principal Investigator, Burke Medical Research Institute
Burke Medical Research Institute
White Plains, New York, 10605
United States
Additional Information:
Study ID Numbers: IA0027;
Study Start Date:
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00013923
Other Alzheimer Disease Studies:
1. Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II
2. The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
3. The Depression in Alzheimer's Disease Study (DIADS)
4. Electrophysiologic Measures of Treatment Response in Alzheimer Disease
5. Serotonergic Pharmacotherapy for Agitation of Dementia
Related Studies:
Other Alzheimer Disease Clinical Trials
Other New York Clinical Trials
Other White Plains Clinical Trials
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
|
|
|
|
|
|
|
|
